An observational case series to assess the effects of intravitreal Bevacizumab on eyes with neovascular glaucoma - Bevacizumab in neovascular glaucoma

Phase 1

• Conditions: eovascular Glaucoma; MedDRA version: 8.1Level: LLTClassification code 10062891Term: Neovascular glaucoma

• Registration Number: EUCTR2006-004826-10-GB
• Lead Sponsor: Moorfields Eye Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2006-09-28
• Last Update Posted: 21 August 2017

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

21 years or older
Willingness to comply
Signed informed consent
Diagnosis of neovascular glaucoma in at least one eye
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Any patient uncooperativeness that restricts adequate examination of the eye

Any concurrent infectious/noninfectious conjunctivitis or keratitis in either eye

Any history of allergic hypersensitivity or poor tolerance to any components of the preparations used in this trial

Females of childbearing potential not using reliable means of birth control

Pregnant or lactating females

Any clinically significant, serious, or severe medical or psychiatric condition

Participation (or current participation) in any investigational drug or device trial within 30 days prior to Visit 1

Inability to understand the trial procedures, and thus inability to give informed consent

Serious systemic, psychological or ocular disease

Unwillingness to accept the risks associated with intravitreal injections.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified